The likelihood of recurrence in breast cancer patients with hormone receptor-positive (HR-positive) tumors is influenced by clinical, histopathological, and molecular features. Recent studies suggested that activated STAT3 (pSTAT3) might serve as a biomarker of outcome in breast cancer patients. In the present work, we have analyzed the added value of pSTAT3 to OncotypeDx Recurrence Score (RS) in patient prognostication. We have found that patients with low RS (<26) and low pSTAT3 might represent a population at a higher risk for cancer recurrence. Furthermore, we have observed that a positive pSTAT3 score alone can be a favorable marker for patients with HR-positive breast cancer under the age of 50. In an era of personalized medicine, these findings warrant further appraisal of chemotherapy benefit in this population.
Bibliographical noteFunding Information:
Funding: This study was funded by a Clinical Research Career Development Award from the Israel Cancer Research Fund grants (16-116-CRCDA), the Israeli Cancer Research Association, and the Raymond F. Schinazi International program.
© 2022 by the authors. Licensee MDPI, Basel, Switzerland.
- Early breast cancer
- Recurrence score